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Abstract
An iterative design strategy using three criteria was utilized to develop a peptidase-resistant
substrate peptide for protein kinase B. Libraries of peptides possessing non-native amino acids
were screened for time to 50% phosphorylation, degradation half-life within a lysate, and
appearance of a dominant fragment. The lead peptide possessed a half-life of 92 ± 7 and 16 ± 2
min in HeLa and LNCaP cytosolic lysates, respectively, representing a 4.6- and 2.7-fold lifetime
improvement over that of the starting peptide. The redesigned peptide possessed a 4.5-fold
improvement in phosphorylation efficiency compared to the starting peptide. The same peptide
fragments were formed when the lead peptide was incubated in a lysate or loaded into single cells
although the fragments formed in significantly different ratios suggesting that distinct peptidases
metabolized the peptide in the two preparations. The rate of peptide degradation and
phosphorylation was on average 0.1 ± 0.2 zmol pg−1 s−1 and 0.04 ± 0.08 zmol pg−1 s−1,
respectively, for single LNCaP cells loaded with 4 ± 8 μM of peptide. Peptidase-resistant kinase
substrates should find wide-spread utility in both lysate-based and single-cell assays of kinase
activity.
INTRODUCTION
Protein kinase B (PKB, also known as Akt) is responsible for regulation of many cell
functions, such as survival under stress, cell proliferation, and apoptosis.1–3 Interest in PKB
has steadily increased due to its role in enabling cells to survive stressful conditions, namely
in preventing apoptosis in cells normally targeted for programmed cell death.4 The PKB
cascade and its upstream constituents have been implicated in tumor progression and
survival in a wide array of cancers, including pancreatic, breast, and prostate tumors.5
Strategies to monitor PKB activity in tumor cells are needed to identify which patients
would benefit from inhibitors of PKB as well as in identifying optimal therapeutic
concentrations. Analysis of PKB activation can be performed on cell lysates using Western
blots in which phosphorylated residues on PKB are probed with phosphospecific antibodies
to infer PKB activity.6 A new technology incorporating isolelectric focusing within a
capillary followed by immunoblotting permits the analysis of smaller cell numbers than a
Western blot.7 However, neither of these techniques enable measurement of PKB activation
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at the single-cell level. Alternative methods that use phosphospecific antibodies to probe
PKB activity at the single cell level include immunocytochemistry, phosphoflow, and
cytometry by time of flight (CyTOF).8–11 The latter two methods are designed for non-
adherent cells and all require cell fixation and permeabilization prior to measurement.
Additionally, immunocytochemical staining of adherent cells identifies the presence of
phosphorylated PKB but is generally considered to be non-quantitative.12 Indicators
employing fluorescent proteins have been developed to measure PKB activity at the single-
cell level by monitoring fluorescence resonance energy transfer between two fluorescent
proteins.13, 14 However, these indicators require transfection of DNA into cells, making their
use in primary cells challenging. Capillary electrophoresis has also been used to measure
PKB activity in single cells; however, this strategy requires use of a fluorescently-tagged
substrate peptide which can have a very short lifetime in cells, substantially limiting the
technique’s utility.15–17
Peptide substrates have been used extensively in biomedical research to assay kinase activity
due to the ease of peptide design and synthesis and the ability to construct extensive peptide
libraries for screening and optimization. As part of these endeavors, peptides serve as assay
substrates for kinases obtained in pure form, from cell lysates, and even in single cells.18–21
However, peptides often possess limited lifetimes in the cellular milieu due to the presence
of peptidases which can degrade them. Multiple strategies have been employed to stabilize
peptides against degradation, including cyclization, terminus modifications, and inclusion of
non-native amino acids. Peptide cyclization yields degradation-resistant peptides, but this
often results in poor substrate recognition by the kinase and these constructs can be
synthetically challenging.22, 23 Modifications to the C- and N-terminus are relatively simple
to accomplish and provide protection against amino- and carboxy-peptidases, but not
endopeptidases.24 Terminal modifications can be used in combination with non-native
residues, including N-methylated and D-amino acids, to impart additional stability to peptide
bonds.16, 25, 26 These non-native residues are readily available commercially and are simply
incorporated into peptides utilizing standard solid phase peptide synthesis. Peptides with
non-native residues generally suffer greatly diminished kinase-substrate properties and the
design of kinase substrates with non-native amino acids remains challenging.26 However,
peptidase-resistant substrates would be of wide utility throughout biomedical research in
assays of kinase activity in the presence of cellular constituents.
This work develops an iterative strategy to screen rationally designed peptides for their
suitability to act as a kinase substrate in a cell lysate. Three criteria, time to 50%
phosphorylation, half-life within a lysate, and appearance of a dominant fragment over time,
were utilized to screen small libraries to design a degradation-resistant peptide substrate for
PKB activity. Cytosolic lysates and purified kinase assays were utilized to rapidly assess
synthetic peptides for their peptidase resistance as well as their ability to act as a substrate.
Cleavage sites in peptides incubated in a cell lysate were characterized using capillary
electrophoresis. Fluorescent peptide fragments were identified by comparison of their
migration times with those of synthesized standards while the amount of each fragment was
quantified from its fluorescence. Identification of cleavage sites permitted iterative
replacement of amino acids with either non-native residues or more suitable native residues.
Substitution success was then reassessed using the three criteria above and new substitutions
incorporated based on these results until a peptidase-resistant PKB substrate was identified.
This designed substrate was used to assay PKB activity in single prostate cancer cells in the
presence and absence of a PKB inhibitor. The heterogeneity of substrate phosphorylation,
kinase inhibitor performance, and peptidase activity in single cells was also evaluated.
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(HCTU), 9-fluorenylmethoxycarbonyl (Fmoc) amino acids and resins were obtained from
ChemPep or Novabiochem and 6-carboxyfluorescein (6FAM), N-Hydroxybenzotriazole
(HOBt), Fmoc-Nα-Me-Arg(Mtr)-OH and were purchased from AnaSpec. Fmoc-β-
HArg(Pbf)-OH was obtained from AAPPTec. Fmoc-α-MeAla-OH, and Fmoc-Phe(F5)-OH
were purchased from Advanced ChemTech. All other peptide synthesis reagents were
purchased from Aldrich or Fisher. Active PKBα enzyme was purchased from Millipore.
Wortmannin was obtained from LC Laboratories. Bovine serum albumin was procured from
Calbiochem. Roswell Park Memorial Institute Media (RPMI-1640) and Dulbecco’s
Modified Eagle Medium (DMEM) were purchased from Cellgro. Penicillin/streptomycin
was obtained from Gibco and fetal bovine serum (FBS) was purchased from Atlanta
Biologicals. All other chemicals used in assays were purchased from Fisher or Sigma.
Peptide Synthesis
Full-length substrate peptides amidated on the C-terminus were synthesized via standard
Fmoc peptide synthesis (Prelude Peptide Synthesizer, Protein Technologies, Tucson, AZ) on
TGR resin (supplemental information). Peptide fragment standards with a free carboxylic
acid on the C-terminus were synthesized using the same strategy but starting with a 2-
chlorotrityl chloride resin. The N-terminus of all peptides was labeled with fluorescein.
in vitro Kinase Assay
Protein kinase assays were performed at 30 °C in assay buffer [8 mM MOPS (3-(N-
morpholino) propanesulfonic acid), pH 7.0, 0.2 mM EDTA, 4 mM MgCl2, 1 mM ATP] with
PKBα kinase (6 nM) and substrate (25 μM). Aliquots were removed from the reaction
mixture at various times and the reaction was halted by heating at 90 °C for 4 min.
Replicates were performed with different purified enzyme aliquots at different times. The
average and standard deviation of triplicate measurements were reported. The amount of
peptide phosphorylation was measured using capillary electrophoresis coupled with laser-
induced fluorescence detection (CE-LIF).
Measurement of Peptide Degradation in a Cell Lysate
A HeLa or LNCaP cell lysate was prepared as previously described.16 Assessment of
peptide degradation was performed by mixing peptide substrate (1 μM) with cell lysate (3
mg mL−1 total cell protein) and incubating at 37 °C. Aliquots were removed and stopped by
adding HCl to a final concentration of 100 mM. A 0 min timepoint was prepared by adding
the HCl to the lysate prior to the addition of the peptide. Reaction mixtures were then
separated and detected with CE-LIF. Peptide fragments were identified by adding standards
(250 nM) to the HCl-terminated aliquots and comparing the electropherograms with and
without the added standard. Replicates were performed with different cytosolic lysates at
different times. The average and standard deviation of triplicate measurements were
reported. The average initial degradation and fragmentation rates were calculated using the
initial and 5 min time points by monitoring the change in peptide quantity divided by the
change in time per amount of cytosolic protein. The units are defined as zmol of peptide per
pg of total cytosolic protein per s (zmol pg−1 s−1).
Measurement of Kinetic Parameters
Protein kinase assays were performed as described in the in vitro kinase assay section with
the following exceptions: substrate concentrations ranged from 0.5 to 30 μM; and PKBα
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enzyme concentration was 1 nM for peptide I and 6 nM for peptide VI-B. The immobilized
metal ion affinity-based fluorescent polarization (IMAP) assay (Molecular Devices
Corporation, Sunnyvale, CA) was used to measure the amount of phosphorylated peptide in
reaction mixtures.
Single Cell Capillary Electrophoresis
Single cell CE was performed using a custom made CE system with LIF detection, as
described previously.16 Fused silica capillaries [30 μm inner diameter, 360 μm outer
diameter, (Polymicro Technologies, Phoenix, AZ)] had a total length of 38 cm and an
effective length of 21.5 cm. For peptide I, the electrophoretic buffer was 100 mM borate and
100 mM SDS, pH 7.7 and a field strength of 315 V cm−1 was applied. For peptide VI-B, the
electrophoretic buffer was either 300 mM borate, pH 7.5 or 100 mM borate and 7 mM SDS,
pH 7.7, with a field strength of 260 V cm−1. In all instances, electrophoresis was initiated by
application of a negative voltage to the outlet while the inlet reservoir was held at ground.
Cells were perfused with extracellular buffer (ECB; 135 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 1 mM CaCl2, and 10 mM HEPES, pH 7.4, 37 °C) during experiments, with the flow
turned off immediately prior to lysis and loading into the capillary. Laser-based lysis was
achieved with a focused Nd:YAG laser as previously described27 and the cell contents were
electrokinetically loaded into the capillary by applying −3 kV to the capillary outlet while
holding the inlet at ground. To identify the peptide fragments formed in a cell, standards of
peptide fragments (100 nM) were hydrodynamically loaded into the capillary following the
contents of a cell previously microinjected with the full-length peptide. A voltage was then
applied across the capillary to initiate electrophoretic separation. These electropherograms
were compared to electropherograms with no standard co-injected to determine if that
peptide fragment was formed. To calibrate the amount of peptide on the electropherograms,
a known concentration of standard of each intact peptide was hydrodynamically loaded into
the capillary, electrophoresed, and the area under the peak calculated. Poiseuille’s equation
was utilized to estimate the amount of peptide injected.28
RESULTS AND DISCUSSION
Selection of the Starting Peptide
The starting peptide I (6FAM-GRPRAATFAEG) was based on the consensus sequence
RPRAATF, determined in a library screen to be phosphorylated by PKB, but not
phosphorylated by two other closely-related kinases, p70 S6 Kinase and MAP kinase
activated protein kinase-1, the only peptide screened in the library with these properties.29
Furthermore, in a large multiplexed assay to analyze substrate specificity of 26 kinases,
peptide I was found to be relatively selective for PKB.30 Peptide I was efficiently
phosphorylated by purified PKB in vitro (Supplementary Figure S1). Two cell types with
upregulated PKB activity were chosen for this proof-of-principle work. LNCaP cells, a line
derived from a human metastatic prostate adenocarcinoma, have decreased PTEN, a
phosphatase with actions that lead to increased PKB activation.31, 32 HeLa cells, a line
derived from a human cervical adenocarcinoma, overexpress upstream components of PKB,
resulting in increased PKB activity.33
In order to identify the initial peptide bond hydrolyzed in a cellular environment, peptide I
was incubated in a HeLa or LNCaP cell lysate. Aliquots were removed over time and CE-
LIF was utilized to quantify the peak area of fluorescent species over time. At time zero in
both the HeLa and LNCaP cytosolic lysates, a single peak with a migration time identical to
that of the intact substrate was seen (Figure 1A). However, as the incubation time was
increased, peptide I was rapidly metabolized with a lifetime of 20 ± 2 and 6 ± 0.9 min in the
HeLa and LNCaP lysate, respectively (Figure 1, Supplementary Figures S1 and S2). Under
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these conditions and when normalized for total cytosolic protein, peptide I was broken down
at an average initial rate of 0.12 ± 0.01 and 0.4 ± 0.06 zmol pg−1 s−1 in the HeLa and
LNCaP lysates, respectively. In both the HeLa and LNCaP lysate, multiple additional peaks
formed over time with similar initial rates. This suggested that in these lysates, several
different peptide bonds could be utilized as the initial site of hydrolysis. By 60 min, six
peaks other than that due to the starting peptide were present in the lysate and the original
peptide had decreased to approximately 10% and 0% of all species present in the HeLa and
LNCaP lysate, respectively. Since the cytosolic lysates did not possess peptidase or
phosphatase inhibitors or added ATP, it was likely that the six additional peaks were
proteolytic fragments of the starting peptides. The significantly shorter lifetime of the
peptide in the LNCaP lysate relative to the HeLa lysate was most likely due to the large
amounts of proteases synthesized by cells of the prostate lineage.34
To identify which peptide fragments were formed in the cell lysates, standards of all
possible fluorescent fragments of peptide I were synthesized and the migration time of each
standard compared to that resulting from the cell lysates. Under the electrophoretic
conditions utilized, all fragment standards were present as a single major peak and each
migrated at a unique time. Each of the peaks generated in the HeLa and LNCaP lysates
matched to a single standard fragment (Figure 1B, C, F). After incubation in the HeLa lysate
for 60 min, two peptide fragments (peptides k and i, Figure 1F) each totaled approximately
20% of all species present, while the remaining four peptide fragments (peptides h, g, f, and
e) each comprised less than 10% of all species present. After 60 min in the LNCaP lysate,
the same 6 peptide fragments were present although in different amounts and peptide k was
present as the dominant species. From these data, no clear initial bond was identified as a
primary site of hydrolysis in either cell lysate.
Strategy for Design of Peptidase-Resistant PKB Substrate
Since there was no clear initial peptidase cleavage site on peptide I for either cell lysate, a
strategy to repeatedly generate a small library incorporating altered peptide residues
followed by screening was utilized. Each library targeted a single residue for modification
and was screened for the time for 50% phosphorylation by PKB (t50%P) as well as for the
peptide lifetime (t1/2) and the appearance of a dominant fragment in a HeLa cell lysate
(Figure 2). The appearance of a dominant hydrolysis site narrowed the choice of residues for
targeted modifications and offered a rational next step in peptide modification. After
identification of the optimal peptide sequence in the library, all possible fluorescent
fragments were synthesized to identify cleavage sites to target for subsequent alterations. A
second small library was generated followed by rescreening for t50%P and t1/2 and dominant
fragment formation. Successive iterations of this process led to identification of multiple
cleavage locations that were stabilized to yield a longer-lived substrate for PKB.
Characterization of Peptides Following Arginine Replacement
Peptide modification initially targeted the amino-terminal alanine but this library failed to
produce peptides that could act as PKB substrates (supplementary information).
Consequently the arginine carboxy-terminal to the proline was targeted since cleavage at
this site yielded peptide i, a three-residue peptide and the most abundant fragment formed in
the HeLa lysate after 45 min of incubation with peptide I (Figure 1). Mono- and di-methyl-
substituted, β-, and D-arginine are readily available derivatives that can impart stability
against proteolysis.25 These modified arginine residues were utilized to synthesize peptides
III-A through III-D (Table 1) and t1/2 and t50% P were measured for each peptide. These
peptides showed no improvement in t1/2 over peptide I, with values ranging from 2 to 17
min. Three of the four peptides showed no evidence of phosphorylation, while the N-
methylated arginine-substituted peptide (III-B) possessed a t50% P of 1013 min, more than
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50X longer than peptide I. When the fragment standards of peptide III-B were generated and
utilized to identify the fragments formed in the lysate, the cleavage at the 3-mer site or Arg-
Pro bond was eliminated. After 60 min, the 6-residue fragment generated by hydrolysis of
the alanine-threonine bond was the dominant fragment, comprising 92% of all peptide
present within 15 min. Although III-B possessed poorer properties than the starting
substrate, it did yield a dominant fragment upon incubation with a cell lysate and a single
preferred hydrolysis site that could be targeted for modification. For this reason, peptide III-
B was used as the template in all subsequent optimization rounds.
Characterization of Peptides Following the Replacement of the Carboxy-Terminal Alanine
The alanine residue located at the alanine-threonine cleavage site of III-B was targeted for
modification since hydrolysis of this peptide bond yielded the dominant fragment when III-
B was incubated in a HeLa cell lysate. Non-native derivatives of alanine, β- and D-alanine,
were substituted for the alanine (peptides IV-A and IV-B, Table 1). Furthermore, since the
active site of PKB possesses a hydrophobic pocket near the phosphorylatable threonine and
is adjacent to a localized region of positive potential,35 two hydrophobic residues (peptides
IV-D and IV-E) and a glutamic acid (peptides IV-F) were also inserted in place of the
alanine (Table 1). The t1/2 and t50% P were measured for each of the peptides IV-A through
IV-E. Four peptides displayed longer t1/2 values than III-B, and one peptide, IV-D,
demonstrated a t50% P of 30 min, on the same order of magnitude as that for peptide I and
over 30X faster than that of peptide III-B. Additionally, when the fragments of peptide IV-D
were analyzed, the dominant initial fragment in the HeLa lysate was the 8-residue fragment
generated when the phenylalanine-alanine bond was hydrolyzed. Thus peptide IV-D was
selected as the next lead peptide.
Characterization of Peptides Following Phenylalanine or Alanine Replacement
The next residues targeted for modification were the two amino acids flanking the cleavage
site of the most abundant fragment of peptide IV-D. Pentafluorophenylalanine
(Supplementary Figure S4) was substituted in place of the phenylalanine to impart
additional hydrophobicity to the position (peptide V-A).36 In addition, the non-native
derivatives D-alanine and sarcosine (Supplementary Figure S4) were inserted in place of the
alanine to investigate substrate suitability (peptides V-B and V-C). Two peptides possessed
t1/2 values 5X greater than that of peptide IV-D while peptide V-B displayed the greatest
resistance to proteolysis (t1/2 of nearly 900 min, over 60X greater than that of IV-D). Of
these peptides, only peptide V-C was phosphorylated at a rate (t50% P of 21 min) similar to
that of IV-D. Furthermore, V-C displayed upon lysate incubation a single fragment which
formed over time, the 9-mer peptide generated by hydrolysis of the sarcosine-glutamic acid
bond (40% of the total peptide present after 60 min). Based on this single hydrolysis
position, peptide V-C was selected for further modifications.
Characterization of Peptides Following Truncation of the Substrate
As illustrated by the consensus sequence, RPRAATF (where T is the site of
phosphorylation), the amino terminal sites play the predominant role in PKB substrate
recognition. Thus removal of the two carboxy-terminal residues from the lead peptide V-C
might not significantly alter the suitability of the substrate for PKB. Since the only fragment
formed when peptide V-C was incubated in the cytosolic lysate was the 9-residue fragment,
this truncated peptide (peptide VI-A) was assessed for its stability over time in a HeLa cell
lysate. Additionally t1/2 and t50% P for a methyl-alanine substituted 9-mer (peptide VI-B)
was also measured. The t1/2 of peptide VI-A indicated that this peptide was significantly less
stable than the parent peptide V-C. However, peptide VI-B possessed a t1/2 of 92 ± 7 min,
similar to that of peptide V-C. When the peptides were incubated with PKBα, t50% P for VI-
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B was similar to that of peptide V-C. Based on these combined properties, peptide VI-B was
selected for further characterization.
Characterization of Lead Peptide VI-B in Cytosolic Lysates
Although the lead peptide VI-B was more stable than peptide I in a HeLa cell lysate, it was
still hydrolyzed into four fragments (Supplementary Figure S5). The latter were identified
by synthesizing and electrophoresing all possible fluorescent fragments. Each peak in the
lysate mixture co-migrated with a single standard peak (Figure 3B). Peptide p, which was
the fragment present in the highest amount, comprised 20% of all species after 60 min and
formed at an average initial rate of 0.02 ± 0.002 zmol pg−1 s−1 (Figure 3D). Three additional
peaks also formed in the HeLa lysate, but on much slower timescales than peptide p (Figure
3D). The parent peptide was degraded at an average initial rate of 0.03 ± 0.004 zmol pg−1
s−1, and approximately 60% remained after 60 min.
Peptide VI-B was also incubated in a LNCaP cytosolic lysate, a more aggressive proteolytic
environment, and fragment formation over time was assessed (Figure 3E, Supplementary
Figure S6). Only three fragments were seen in addition to the intact parent peptide, with
peptide p making up 90% of all peptide present after 60 min. The rate of breakdown of the
intact parent in the LNCaP lysate was 0.16 ± 0.03 zmol pg−1 s−1, over 5X faster than
breakdown in the HeLa lysate. Peptide p formed at a rate essentially as fast as the parent was
degraded, at 0.14 ± 0.02 zmol pg−1 s−1. Two additional fragments, peptides o and n, formed
at much slower rates, similar to the result obtained in the HeLa lysate. As expected in the
cell line with more the aggressive proteolytic environment, peptide bond hydrolysis proved
to be much faster, although the primary cleavage location remained the same.
The kinetic parameters KM and kcat were determined for peptide I and the lead peptide VI-B
in order to compare the substrate efficiency of these peptides. Varying concentrations of
each peptide were incubated with PKB and the initial reaction velocity was calculated for
each substrate concentration. Peptide I exhibited a better KM than peptide VI-B (3 μM
compared to 23 μM) but a poorer kcat (3,400 min−1) relative to that of VI-B (5,800 min−1)
leading to a 4.5-fold better efficiency for VI-B over peptide I.
Characterization of Peptide Degradation in Single LNCaP Cells
Peptides I and VI-B were microinjected into single LNCaP cells and incubated for 90 s prior
to lysis and electrophoresis to characterize peptide behavior. Peptide I was degraded into 6
fragment peaks while peptide VI-B was degraded into 2 fragment peaks (Supplementary
Figure S7). Thus, peptide VI-B was selected over peptide I for further characterization in
single cells. To quantify the amount of peptide VI-B degradation and phosphorylation within
intact cells, the peptide was microinjected into single LNCaP cells (n = 19) and incubated
for 5 min prior to cell lysis and CE-LIF. Four peaks were observed, with intact, non-
phosphoryated, parent peptide accounting for 15 ± 5% of all species present. The parent
peptide was degraded into one of two fragment peaks (peptides m or p) or converted to
phosphorylated product (Figure 4A). In addition, the major peptide fragment identified in
single cells was peptide m (40% of total peptide present), the 8-residue fragment seen only
in small amounts in the LNCaP lysate studies (Figure 3E). The major fragment seen in the
LNCaP lysate studies, peptide p, was present only as a minor species in the single cells.
Assuming a cell volume of 1 pL and a total protein concentration of 100 mg mL−1,37 the
intact peptide was eliminated at an average rate of 0.1 ± 0.2 zmol pg−1 s−1, similar to the
breakdown rate measured in LNCaP cytosolic lysates. The rate of degradation of the intact
parent peptide was linearly dependent on the peptide concentration (4 ± 8 μM) in the cell
(Figure 4C), with a linear regression analysis yielding an R2 value of 0.9899.
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Phosphorylation of Peptide VI-B in Single LNCaP Cells
Five min after introduction of VI-B into single cells, the percentage of intact peptide that
was phosphorylated ranged from 0 – 80% (58 ± 26%). The amount of phosphorylated
peptide present varied linearly with respect to the amount of peptide microinjected into the
cell (Figure 4D). A linear regression analysis of the rate of phosphorylation yielded an R2
value of 0.9401, indicating greater cell-to-cell variability in the amount of peptide
phosphorylated relative to that degraded in cells even after correction for the amount of
peptide loaded into cells. This may be due to a greater variation in the concentration of
active kinase molecules in single cells relative to that of the peptidases. Flow cytometry-
based measurements suggest that the numbers of protein molecules per cell for enzymes
involved in proteolytic degradation are tightly regulated and thus have relatively little cell-to
cell variation.38 By contrast, the copy number for molecules acting as components of
signaling cascades responsive to environmental stimuli generally have significant noise or
much greater variation in the cell-to-cell copy numbers.
Inhibition of PKB Activity in Single Cells
Wortmannin is a selective inhibitor of PI3-Kinase when used in nanomolar concentrations,
which leads to decreased PKB activation.39 LNCaP cells were pre-incubated with 500 nM
wortmannin (10 min) and then loaded with VI-B (n = 10). After 5 min, cells were
individually lysed and their contents separately electrophoresed. Four peaks (intact parent,
phosphorylated substrate, and fragments m and p) were identified in these cells as in the
cells without wortmannin (Figure 4B). There was no statistical difference in the amount of
degradation observed when compared to cells with no pre-treatment (p-value of 0.77; Figure
4C). Formation of phosphorylated product was substantially decreased (13% ± 12%)
compared to that for cells not pretreated with wortmannin (p-value of 1.1 × 10−6). While
wortmannin also inhibits mTOR, myosin light chain kinase (MLCK), and
phosphatidylinositol 4-kinase (PI4K) but at micromolar concentrations,39 inhibition of
substrate phosphorylation by these low concentrations of wortmannin suggested that the
peptide was predominantly acting as a substrate for PKB.
CONCLUSION
An iterative design and screening process was used to identify and stabilize locations
susceptible to proteolysis in a kinase substrate peptide. Each round of redesign yielded a
substrate with more favorable properties until a peptide resistant to lysate peptidases, yet
suitable as a PKB substrate, was obtained. The optimized peptide displayed similar
fragmentation patterns in lysates from cervical (HeLa) vs prostate (LNCaP) cancer cell lines,
but the rates of hydrolysis were dramatically different. The relatively high proteolytic rates
observed in the prostate-derived cells was likely due to the fact that normal prostate produce
an abundance of proteases. The rate of proteolysis in the LNCaP lysate was similar to that
seen in the single LNCaP cells. Remarkably, the primary cleavage locations differed
between lysates and single cells, suggesting that different peptidases may access the peptide
in these two conditions, thereby indicating that lysates do not always provide an accurate
mimic of the intact cell. Although substantial variability existed in the percentage of peptide
degraded in single cells, this variability was a consequence of the variation in the amount of
peptide loaded into cells i.e. the final intracellular peptide concentration. With regard to
phosphorylation, substantial variability existed between single cells, indicating differing
amounts of kinase activity in cells within the same population. These measurements are
consistent with other measures of single cell variability, such as that seen in flow cytometry
and microscopy.40, 41
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Degradation of the starting peptide I in cytosolic lysates. (A) – (C) Electropherograms of
peptide I after incubation in a HeLa or LNCaP lysate for 0 min (A) for 30 min in HeLa (B)
or for 30 min in LNCaP (C) cytosolic lysate. (D) Formation of peptide fragments over time
in HeLa lysate. (E) Formation of peptide fragments over time in LNCaP lysate. The symbols
are defined as: black closed circle (peptide a or starting peptide); pink open circle (peptide
i); red closed square (peptide k); green open square (peptide h); orange closed triangle
(peptide g); black open triangle (peptide f); and blue closed diamond (peptide e). (F) The
uppercase letters are the single amino acid abbreviations for the starting peptide sequence.
The lowercase letters represent cleavage locations that form the indicated fluorescent
peptide fragments.
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Schematic of rational peptide substrate design. (A) Synthesize starting peptide. The different
geometrical shapes represent different amino acids. (B) Synthesize all possible fluorescent
peptide fragments of starting peptide (B1) and incubate starting peptide with active enzyme
and ATP (B2). (C) Use CE-LIF to analyze degradation and identify peptide fragments
formed (C1) and to assess phosphorylation over time (C2). (D) Determine the half-life of the
peptide in the lysate (D1) and the time required for the peptide to reach 50%
phosphorylation (D2). (E) Of the peptides showing favorable t1/2 and t50% P values, identify
whether a preferred cleavage site exists in the peptide. (F) Synthesize a library of new
peptide substrates with non-native amino acids adjacent to the most susceptible bond in the
lead peptide. (G) Reiterate through steps (B) – (F) until a suitable, long-lived substrate is
obtained.
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Degradation of the lead peptide VI-B in cytosolic lysates. (A) – (C) Electropherograms of
peptide I after incubation in a HeLa or LNCaP lysate for 0 min (A) for 30 min in HeLa (B)
or for 30 min in LNCaP (C) cytosolic lysate. (D) Formation of peptide fragments over time
in HeLa cell lysate. (E) Formation of peptide fragments over time in LNCaP cell lysate. The
symbols are defined as: closed circle (peptide l); open circle (peptide p); closed square
(peptide o); open square (peptide n); and closed triangle (peptide m). (F) The uppercase
letters are the single amino acid abbreviations for the lead peptide sequence, MeArg is N-
methylated arginine, and MeAla is N-methylated alanine. The lowercase letters represent
cleavage locations that form the indicated fluorescent peptide fragments.
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Electropherograms of single LNCaP cells 5 min after microinjecting the lead peptide QW-
VII-48F without (A) or with pre-treatment with wortmannin (B). The lowercase letters mark
the peaks due to the intact peptide or peptide fragments identified in Figure 3F and the *
labels the peak due to the phosphorylated peptide product. Two representative cells are
shown for (A) and for (B). (C) Rate of degradation of parent peptide as a function of amount
microinjected in single cells with (open squares, n = 19) and without (closed circles, n = 10)
pre-treatment with wortmannin. (D) Rate of phosphorylation as a function of amount
microinjected in single cells.
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Table 1
Peptide Properties.
Peptide Sequence t50%P (min) t1/2 (min) Initial Dominant Fragment
I 6FAM-GRPRAATFAEG 17 20 5-mer
III-A 6FAM-GRP-βArg-AATFAEG NP 9 ND
III-B 6FAM-GRP-MeArg-AATFAEG 1013 2 6-mer
III-C 6FAM-GRP-Arg(Me2)-AATFAEG NP 8 ND
III-D 6FAM-GRP-DArg-AATFAEG NP 17 ND
IV-A 6FAM-GRP-MeArg-A-βAla-TFAEG >105 14 ND
IV-B 6FAM-GRP-MeArg-A-DAla-TFAEG >105 32 ND
IV-C 6FAM-GRP-MeArg-A-Glu-TFAEG 679 37 ND
IV-D 6FAM-GRP-MeArg-A-FTFAEG 30 14 8-mer
IV-E 6FAM-GRP-MeArg-A-MePhe-TFAEG 125 2 ND
V-A 6FAM-GRP-MeArg-AFT-Phe(F5)-AEG 174 88 ND
V-B 6FAM-GRP-MeArg-AFTF-DAla-EG 306 895 9-mer
V-C 6FAM-GRP-MeArg-AFTF-Sarc-EG 21 84 9-mer
VI-A 6FAM-GRP-MeArg-AFTF-Sarc-NH2 36 13 ND
VI-B 6FAM-GRP-MeArg-AFTF-MeAla-NH2 34 92 5-mer
a t50% P is the time required for 50% of the peptide to be phosphorylated and bt1/2 is the half-life of the intact peptide in a HeLa cytosolic lysate.
NP = no phosphorylation. ND = not determined. Peptides shown in bold were used as base peptides for further modification in the next iteration.
The amino acids are represented by their standard one letter code except for the following, which are defined as: βAla (Beta-alanine), MeAla (N-
methylated alanine), DAla (D-alanine), βArg (Beta-arginine), MeArg (N-methylated arginine), Arg(Me2) (N-ω,ω-dimethyl-L-
arginine(symmetrical)), MePhe (N-methylated phenylalanine), Phe(F5) (pentafluorophenylalanine), and Sarc (sarcosine, or N-methyl glycine).
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